ArticleBMC pulmonary medicine2025
Association between lateral pterygoid muscle index as a predictor for sarcopenia and overall survival in non-small cell lung cancer patients with brain metastasis.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsSarcopenia has emerged as a significant prognostic factor for lung cancer. However, it remains unclear how the lateral pterygoid muscle index (LPMI) calculated based on the lateral pterygoid muscle area correlates with sarcopenia in lung cancer patients with brain metastasis (BM). This study aims to determine whether LPMI can serve as a predictor for sarcopenia in lung cancer patients with BM and assess its utility in predicting survival.
methodsThis study retrospectively analyzed the initial brain magnetic resonance imaging (MRI) parameters of non-small cell lung cancer (NSCLC) patients with BM at our hospital between March 2017 and June 2024. We examined the correlation between LPMI and the lumbar skeletal muscle index (LSMI) at the third lumbar vertebra (L3). After adjusting for key prognostic factors, we performed a multivariate Cox regression analysis of overall survival (OS) to evaluate the prognostic significance of LPMI.
resultsA total of 223 patients were included. The LPMI was positively correlated with LSMI in NSCLC patients with BM (r = 0.618, p < 0.001). Multivariate linear regression analysis indicated LPMI was associated with the risk of sarcopenia (β = 0.427,p < 0.001). The optimal cut-off value of LPMI for identifying NSCLC with sarcopenia was 120.06. Multivariate logistic regression showed an increased blood urea nitrogen/creatinine ratio (BUN/Cr) was associated with lower LPMI values (OR = 1.014, p = 0.013). Patients with an LPMI thicker than the median had a longer OS compared to those with an LPMI thinner than the median (9 months vs. 14.5 months, p = 0.011). Multivariate Cox analysis showed a thicker LPMI measurement was a predictor of longer OS (HR = 0.993,p = 0.036).
conclusionsOur results indicate that LPMI has the potential to serve as an alternative diagnostic indicator for sarcopenia in NSCLC patients with BM and as an independent predictor of OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.